Scrip
Mind over matter - the expert view on CNS
11 May 2010
Peter Charlish
Please Login to read the full article.
11 May 2010
Peter Charlish
The CNS field is a $100 billion market, and with ageing populations and unmet needs, the segment is set to grow even further. We spoke to Ben Greener, Datamonitor's head of CNS market analysis, about the likely path of CNS drugs and what companies need to consider when building their...
Please Login to read the full article.
RELATED CONTENT
NEWS
- 2009 results preview: big pharma grapples to varying degrees of success with generic erosion
- Genentech amends trial protocol as FDA gets tough on accelerated cancer drug approvals
- US court stalls federal funding of ESC research, gov to appeal
- Alarming rise in chronic use of meds by American children, Medco report says
ANALYSIS
- Executive Briefing – Brazil emerges as a saviour for pharma
- Executive Briefing – Health technology assessment: a brief look at the EU
COMMENT
Other Informa Comment
FEATURES
- Anti-obesity drugs: an inventor's perspective
- Face-to-Face: Allon targets tau pathology with lead drug davunetide
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
